Long-term Safety and Efficacy Study of Deferiprone in Patients With Pantothenate Kinase-Associated Neurodegeneration (PKAN)
Phase of Trial: Phase III
Latest Information Update: 26 Jul 2019
Price : $35 *
At a glance
- Drugs Deferiprone (Primary)
- Indications Pantothenate kinase-associated neurodegeneration
- Focus Adverse reactions
- Acronyms TIRCON-EXT
- Sponsors ApoPharma
- 23 Apr 2018 Status changed from active, no longer recruiting to completed.
- 17 Apr 2018 This trial has been completed in Germany (end date: 16 Mar 2018) , according to European Clinical Trials Database.
- 22 Mar 2017 Status changed from recruiting to active, no longer recruiting.